Phathom Pharmaceuticals, Inc. — Form 8-K Summary
Business Context and Reporting Period
Phathom Pharmaceuticals, Inc. is a Delaware-based pharmaceutical company. The Form 8-K reports actions taken on January 19, 2022, and was filed on January 25, 2022. The filing concerns executive compensation arrangements under the company’s 2019 Incentive Award Plan.
Key Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial performance metrics.
Material Changes
- On January 19, 2022, the Compensation Committee adopted a form of restricted stock unit (RSU) award agreement for grants under the 2019 Incentive Award Plan.
- The agreement permits vesting based on the applicable grant notice, imposes transfer restrictions, and allows shares to be sold to cover withholding taxes upon vesting.
- RSUs were awarded to executive officers as follows: Terrie Curran, 41,250; Azmi Nabulsi, 19,500; and Anthony Guzzo, 6,000.
- The awards total 66,750 RSUs. Each RSU represents the right to receive one share of common stock upon vesting.
- The RSUs vest in three equal annual installments, subject to the executive’s continued service and the award agreement’s terms.
Outlook, Risks, Contingencies, and Unusual Items
The filing provides no financial guidance or business outlook. The principal conditions affecting the awards are continued service through each vesting date, applicable transfer restrictions, and potential share sales to satisfy withholding tax obligations. The filing does not state the grant-date fair value or expected compensation expense.
Investor Verification Items
- Review Exhibit 10.1 for the complete terms of the RSU award agreement.
- Verify the vesting schedules and any applicable forfeiture or termination provisions in the individual grant notices.
- Assess the potential dilution from the 66,750 RSUs and any related withholding-tax share sales.
- Confirm the grant-date accounting treatment and compensation expense in subsequent periodic filings.